**PRESS RELEASE**

**New Regulator For Blood Cancer Development Identified**

**A research team led by physicians of the Karl Landsteiner University of Health Sciences in Krems (KL Krems) uncovers a pivotal role for a regulator protein in tumour bone marrow angiogenesis.**

**Krems, 23th June 2021 – A specific regulatory protein significantly influences the development of tumour-inducing blood vessels in the bone marrow of blood cancer patients. Using a series of different experiments, the team identified that a transcription factor known as JunB is central for the formation of new blood vessels in the bone marrow of patients suffering from multiple myeloma (MM). The findings, which have been published in the journal Leukemia, could pave the way for novel treatment approaches for this still incurable disease.**

MM is the second most common form of cancer in haematopoietic cells. Despite significant therapeutic advances over the past two decades, MM remains incurable. A critical factor in MM pathogenesis is the formation of new blood vessels in the bone marrow (known as angiogenesis). Exact molecular mechanisms leading to this process are still unknown. By identifying a new key regulator of tumour bone marrow angiogenesis, an international team headed by KL Krems’ Dr Klaus Podar (Department of Internal Medicine II at Krems University Hospital) has now shed more light on this complex mechanism.

**Disease Promotion**

Specifically, the team examined the role of a transcription factor, a protein called JunB, which regulates the production of other proteins. Results demonstrated that JunB regulates the production of so-called angiogenic factors, and thereby contributes to bone marrow angiogenesis, in early MM in particular.

For Dr. Podar and his team, JunB is by no means an unknown player in MM. Indeed, they have analysed the complex functions of this protein in MM pathogenesis for many years. “Our past studies have already demonstrated that JunB promotes tumour cell proliferation, survival and drug resistance,” says Dr. Podar, summing up the findings of his group’s earlier findings. “The fact that we have now also identified a key role for JunB in the formation of blood vessels within the bone marrow underscores the potential value of therapeutically targeting this protein.”

**Wide Range of Supporting Experiments**

Utilizing a wide range of up-to-date methodologies and genetically inducible tumour-cell models, results demonstrated that JunB correlated with the induction of angiogenic factors, VEGF, VEGFB and IGF1, in particular. Consequently, culture media stimulated blood vessel growth upon JunB activation. A key role for JunB in MM bone marrow angiogenesis was further confirmed in an innovative dynamic 3D-model, in an in vivo model, as well as in patient bone marrow sections. Importantly, the researchers’ results also demonstrated that JunB function was independent of low oxygen levels in the tumour microenvironment –

usually a crucial factor for the production of pro-angiogenic factors. As Dr. Podar points out: “This makes JunB a promising therapeutic target. Its inhibition may even prevent the initiation of symptomatic MM.”

In summary, the research team which consists of members from Austria, Belgium, China, Germany, Italy and the US uncovered a new function of the regulator protein JunB in early MM pathogenesis. Together with their previous findings these data strongly support the value of targeting JunB for MM therapy. Molecular research at KL Krems has once again proven that it is geared towards obtaining insights for direct clinical benefit.

**Original Publication:**

JunB is a key regulator of multiple myeloma bone marrow angiogenesis. F. Fan, S. Malvestiti, S. Vallet, J. Lind, J. M. Garcia-Manteiga, E. Morelli, Q. Jiang, A. Seckinger, D. Hose, H. Goldschmidt, A. Stadlbauer, C. Sun, H. Mei, M. Pecherstorfer, L. Bakiri, E. F. Wagner, G. Tonon, M. Sattler, Y. Hu, P. Tassone, D. Jaeger, K. Podar. Leukemia, https://doi.org/10.1038/s41375-021-01271-9

**About Karl Landsteiner University of Health Sciences**

At Karl Landsteiner University of Health Sciences (KL) in Krems, the comprehensive approach to health and disease is a fundamental objective for research and teaching. With its Europe-wide recognized bachelor-master system, KL is a flexible educational institution that is tailored to the needs of students, the requirements of the labor market as well as the scientific challenges. Currently KL hosts about 600 students in the fields of medicine and psychology. The four university hospitals in Krems, St. Pölten, Tulln and Eggenburg ensure clinical teaching and research at the highest quality level. In research, KL focuses on interdisciplinary fields with high relevance to health policy - including medical technology, molecular oncology, mental health and neuroscience, as well as water quality and related health aspects. KL was founded in 2013 and accredited by the Austrian Agency for Quality Assurance and Accreditation (AQ Austria). www.kl.ac.at/en

|  |  |  |
| --- | --- | --- |
| **Scientific Contact**  Priv.-Doz. Mag. DDr. Klaus Podar  Department of Internal Medicine 2  University Hospital Krems  Karl Landsteiner University of Health Sciences  Mitterweg 10  3500 Krems an der Donau  T +43 2732 9004 12355  E klaus.podar@krems.lknoe.at | **Karl Landsteiner University of Health Sciences**  Eva-Maria Gruber  Communication, PR & Marketing (Head)  Dr.-Karl-Dorrek-Straße 30  3500 Krems / Austria  T +43 2732 72090 231  M +43 664 5056211  E evamaria.gruber@kl.ac.at  W http://www.kl.ac.at/ | **Copy Editing & Distribution**  PR&D – Public Relations for Research & Education  Dr. Barbara Bauder  Kollersteig 68  3400 Klosterneuburg / Austria  T +43 664 1576350  E bauder@prd.at  W http://www.prd.at/ |